Brazil has approved Butantan DV, the world’s first single dose dengue vaccine, marking a major milestone in the global fight against dengue.
Butantan DV overview
The vaccine is a live, attenuated tetravalent formulation designed to protect against all four dengue virus types in one shot.
Clinical trials show it is safe and around 80 percent effective across all age groups regardless of previous infection. Researchers also reported strong protection against severe dengue and hospitalisation.
Single dose simplifies rollout
Butantan DV requires only one 0.5 mL dose. This makes mass vaccination faster and easier compared to current two dose vaccines that need long gaps between doses.
Experts believe the simplified schedule will improve coverage in outbreak areas and reduce dropout rates seen in multi dose vaccination programs.
Approval for ages 12 to 59
Brazil’s regulator ANVISA has authorised the vaccine for individuals aged 12 to 59. The decision comes after eight years of trials involving over sixteen thousand volunteers across Brazil.
Additional trials may expand eligibility to younger children and older adults in future
Why this matters
Dengue cases have surged globally with millions infected each year. Warmer temperatures and expanding mosquito habitats are driving the spread into new regions.
Brazil remains one of the most affected countries and health officials say the vaccine will play a key role alongside mosquito control and early diagnosis.
Background
The Butantan Institute began developing the vaccine in 2013. Large scale manufacturing plans are already in progress and rollout across Brazil is expected to begin in 2026. Other dengue affected countries may adopt it after regulatory review.
Also Read This:
Delhi Air Pollution Crisis: Causes, Government Measures, and Steps Citizens Can Take in 2025
Leave a comment